Dr. Sujatha Nallapareddy

Oncology
701 E Hampden Ave, Ste 210, 
Littleton, CO 
Accepting New Patients
Offers Telehealth
701 E Hampden Ave, Ste 210, 
Littleton, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sujatha Nallapareddy is an Oncologist in Littleton, Colorado. Dr. Nallapareddy is rated as an Experienced provider by MediFind in the treatment of Hartsfield Syndrome. Her top areas of expertise are Pulmonary Embolism, Thrombocytopenia, Deep Vein Thrombosis, and Antiphospholipid Syndrome. Dr. Nallapareddy is currently accepting new patients.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Osmania Medical College
Residency
State University of New York at Buffalo
Specialties
Oncology
Licenses
Internal Medicine in CO
Board Certifications
Internal Medicine-American Board Of Internal Medicine (ABIM)
Hematology-American Board Of Internal Medicine (ABIM)
Medical Oncology-American Board Of Internal Medicine (ABIM)
Fellowships
University of Colorado School of Medicine (CU University of Colorado Anschutz Medical Campus)
Hospital Affiliations
The Medical Center Of Aurora & South Hospital
Littleton Adventist Hospital, Centura Health
Kit Carson County Memorial Hospital
Hca-Healthone Dba Swedish Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Rocky Mountain Cancer Centers LLP
701 E Hampden Ave, Ste 210, Littleton, CO 80120

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

3 Total Publications

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Journal: The Lancet. Oncology
Published: July 19, 2012
Similar Doctors
Experienced in Hartsfield Syndrome
Dr. John M. Barnett
Oncology
Experienced in Hartsfield Syndrome
Dr. John M. Barnett
Oncology

Rocky Mountain Cancer Centers LLP

1760 E Ken Pratt Blvd, Ste 302, 
Longmont, CO 
 (44.8 miles away)
303-684-1900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Barnett is an Oncologist in Longmont, Colorado. Dr. Barnett is rated as a Distinguished provider by MediFind in the treatment of Hartsfield Syndrome. His top areas of expertise are Appendix Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast. Dr. Barnett is currently accepting new patients.

Experienced in Hartsfield Syndrome
Dr. Manojkumar Bupathi
Oncology
Experienced in Hartsfield Syndrome
Dr. Manojkumar Bupathi
Oncology

Lone Tree Family Practice PLLC

10103 RidgeGate Pkwy, Ste G23, 
Lone Tree, CO 
 (0.1 miles away)
303-225-0025
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manojkumar Bupathi is an Oncologist in Lone Tree, Colorado. Dr. Bupathi has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Hartsfield Syndrome. His top areas of expertise are Urothelial Cancer, Breast Cancer, Paget Disease of the Breast, and Chromophobe Renal Cell Carcinoma. Dr. Bupathi is currently accepting new patients.

Experienced in Hartsfield Syndrome
Dr. Yousuf A. Gaffar
Hematology Oncology | Hematology | Oncology
Experienced in Hartsfield Syndrome
Dr. Yousuf A. Gaffar
Hematology Oncology | Hematology | Oncology

Portercare Adventist Health System

7700 S Broadway, Hslh Hospitalists Lah, 
Littleton, CO 
 (7.0 miles away)
303-730-8900
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Yousuf Gaffar is a Hematologist Oncology specialist and a Hematologist in Littleton, Colorado. Dr. Gaffar is rated as a Distinguished provider by MediFind in the treatment of Hartsfield Syndrome. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Adult Immune Thrombocytopenia, and Immune Thrombocytopenic Purpura (ITP). Dr. Gaffar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nallapareddy's expertise for a condition
ConditionClose
    View All 29 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile